With ForeseeHome as part of
a home detection program,
you can detect
wet AMD earlier1
Patient was symptomatic with VA of 20/25 when ForeseeHome registers an alert. CNV is confirmed in her left eye by her retina specialist.
Thirteen days after a routine exam with her retina specialist showed no wet AMD, ForeseeHome triggered an alert. Wet AMD was confirmed upon examination.
A patient went in for an exam the day after ForeseeHome triggered an alert. Wet AMD was confirmed in the left eye and treatment was initiated that day. Two months later, his vision had improved from 20/40+2 to 20/25-2.
A ForeseeHome alert brings a patient into her physician’s office in late December 2011. She had not converted to wet AMD, but was brought in for a follow-up exam 4 weeks later. At the follow-up exam in January, her OCT did indicate neovascular AMD, correlating with changes in her ForeseeHome results and second alert on January 27.
A patient was using ForeseeHome for about 6 weeks when an alert was triggered. At the time of the alert, the patient had noticed minimal visual change and had not identified any significant change on her Amsler grid. With the help of ForeseeHome, her physician was able to treat the lesion at the earliest possible stage and preserve the patient’s good vision.
New Brunswick, NJ
After using ForeseeHome daily for about 3 months, an alert was triggered. At the time of the alert, the patient had excellent 20/20 acuity and was asymptomatic, exhibiting no visual acuity changes on the Amsler grid. He immediately saw his retina specialist, who confirmed that he had converted from dry to wet AMD. ForeseeHome detected the visual changes that allowed the patient to be treated before the lesion progressed, preserving his vision.
AMD=age-related macular degeneration; CNV=choroidal neovascularization; OCT=optical coherence tomography; VA=visual acuity.
The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.
The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.